id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-2896-0007,FDA,FDA-2016-N-2896,Request for Extension from Generic Pharmaceutical Association (GPhA),Other,Request for Extension,2016-12-06T05:00:00Z,2016,12,2016-12-06T05:00:00Z,,2016-12-06T21:31:57Z,,0,0,090000648238157f
FDA-2016-N-2896-0008,FDA,FDA-2016-N-2896,Request for Extension from Generic Industry Working Group,Other,Request for Extension,2016-12-06T05:00:00Z,2016,12,2016-12-06T05:00:00Z,,2016-12-06T21:34:17Z,,0,0,09000064823a976b
FDA-2016-N-2896-0004,FDA,FDA-2016-N-2896,Public Meeting on Pre-Market Evaluation of Abuse-Deterrent Properties of Opioid Drug Products; Extension of Comment Period,Notice,Extension of Comment Period,2016-12-05T05:00:00Z,2016,12,2016-12-05T05:00:00Z,2017-01-04T04:59:59Z,2017-01-04T02:00:17Z,2016-29097,0,0,09000064823ded68
FDA-2016-N-2896-0001,FDA,FDA-2016-N-2896,Public Meeting on Pre-Market Evaluation of Abuse-Deterrent Properties of Opioid Drug Products,Notice,Request for Comments,2016-10-06T04:00:00Z,2016,10,2016-10-06T04:00:00Z,2016-12-02T04:59:59Z,2024-11-12T06:15:28Z,2016-24234,1,0,090000648229ef86